About
Many current spatial biology and multiplex immunohistochemistry technologies involve time-consuming methods for panel optimization, validation, and analysis—which typically take weeks to months, slowing down scientific discovery. With SignalStar Multiplex IHC, researchers can generate results in as little as two days with optimized, ready-to-go panels.

Join us for a webinar led by Dr. Sarah Klein, Associate Director of Multiplex Assay Development at Cell Signaling Technology, to learn about SignalStar Multiplex IHC, an innovative technology that empowers spatial biology research that harnesses the synergy of specific primary antibodies and a network of fluorescent oligonucleotides to efficiently amplify the signal of cellular proteins in formalin-fixed, paraffin-embedded (FFPE) tissue samples.

With SignalStar Multiplex IHC, you gain:

  • Rapid Insights: Generate results in 2 days with optimized, ready-to-go panels

  • Visual Clarity: Detect and visualize up to 8 targets in FFPE tissue

  • Amplified Precision: Amplify the signal of targets with low levels of expression

  • Instant Start: Leverage ready-to-go protocols that are validated and optimized to work out of the box

  • Seamless Integration: Easily employ your existing fluorescent imagers



Key Topics Include:
  • How SignalStar Multiplex IHC works—an overview of the mechanics and how it unlocks spatial insights

  • How SignalStar Multiplex IHC demonstrates reproducibility and flexibility

  • How to design experiments efficiently with a user-friendly online panel builder—enabling precision planning


Who Should Attend?
  • Researchers using spatial biology technologies, especially multiplex immunohistochemistry

  • Researchers running high-throughput analyses interested in efficient mid-plex immunohistochemistry assays

  • Translational immuno-oncology researchers exploring the spatial context of tumor microenvironments
Presenter
1694192971-f35a32d8bd9822d4
Sarah Klein, PhD
Associate Director of the Multiplex Assays Group, Cell Signaling Technology
Sarah Klein, PhD, is the Associate Director of the Multiplex Assays Group at Cell Signaling Technology (CST). This group was instrumental in the development and validation of SignalStarTM Multiplex IHC. Dr. Klein has been with CST for 7 years, developing antibody-based solutions in the fields of immunology and oncology. She performed her postdoctoral research at Dana Farber Cancer Institute in Boston, MA, and her doctoral research at MD Anderson Cancer Center in Houston, TX, studying the mechanisms of action for immunotherapeutics used in the treatment of cancer, particularly glioblastomas.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Organization / Company*
Job Title*
Country / Region*
Main Research Area(s)*
Cell Biology
Developmental Biology / Stem Cells
Epigenetics
Immunology
Infectious Disease
Metabolism
Oncology
Genetics / Genomics
Neuroscience
Other:
Other Research Area:
Have a question for Sarah? Ask it here:
utm_bmcr_source
Registration Terms
This event is hosted by the Scientist.com family of companies. Specific brands and sites associated with this event include InsideScientific. By registering and participating, you acknowledge that your personal data will be processed by the webinar platform (BigMarker) and Scientist.com. You also agree to receive email communication from Scientist.com and InsideScientific about this webinar and other programs of similar nature. The sponsor of this webinar is Cell Signaling Technology (CST); by registering and participating, you acknowledge that your data will be processed in accordance with CST's Privacy Policy. You will receive email communication from CST about this webinar and programs of similar interest. You can withdraw your consent at any time from these communications.
Scientist.com Privacy Policy
✓ Yes, I consent to the registration terms.*
Cell Signaling Technology Privacy Policy
✓ Yes, I consent to the registration terms.*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.
Powered by BigMarker